SCHEMBL3300936

SCHEMBL3300936

Cc1ccc(=O)n(-c2ccc(Br)cc2Br)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HPGD P15428 2/20 0.46
CYP1A2 P05177 1/20 0.46
BLM P54132 1/20 0.46
HSP90AA1 P07900 1/20 0.37
TLR9 Q9NR96 1/20 0.37
OPRM1 P35372 2/20 0.36
OPRK1 P41145 2/20 0.36
OPRD1 P41143 1/20 0.36
ACHE P22303 1/20 0.35
SRD5A1 P18405 1/20 0.35
MYC P01106 1/20 0.34
NR4A1 P22736 1/20 0.34
MAPT P10636 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
MAPK14 Q16539 2/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4755721 0.94 ALDH1A1 (0.41) ALDH1A1HSD17B10KDM4EHPGDCYP1A2
SCHEMBL3302374 0.87 ALDH1A1 (0.46) ALDH1A1HSD17B10KDM4EHPGDCYP1A2
SCHEMBL3306361 0.79 ALDH1A1 (0.58) ALDH1A1HSD17B10KDM4EHPGDCYP1A2
SCHEMBL3304568 0.75 ALDH1A1 (0.52) ALDH1A1HSD17B10KDM4EHPGDCYP1A2
SCHEMBL3307167 0.75 ALDH1A1 (0.67) ALDH1A1HSD17B10KDM4EHPGDCYP1A2
SCHEMBL3300511 0.74 ALDH1A1 (0.59) ALDH1A1HSD17B10KDM4EHPGDCYP1A2
SCHEMBL3300493 0.73 ALDH1A1 (0.64) ALDH1A1HSD17B10KDM4EHPGDCYP1A2
SCHEMBL3307172 0.73 ALDH1A1 (0.50) ALDH1A1HSD17B10KDM4EHPGDCYP1A2
SCHEMBL10025187 0.72 KDM4E (0.74) ALDH1A1HSD17B10KDM4EHPGDCYP1A2
SCHEMBL3310092 0.72 ALDH1A1 (0.52) ALDH1A1HSD17B10KDM4EHPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099719-A1 COMPOSITION AND METHOD FOR TREATING PROTEINURIA DIEREPHARMA, INC. (US) 2010-04-22 US claimed
US-20090258911-A1 COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES TAO LI JIAN 2009-10-15 US claimed
US-20090005424-A9 Composition and Method for Treating Fibrotic Diseases TAO LI J 2009-01-01 US claimed
US-20070203203-A1 Composition and Method for Treating Fibrotic Diseases TAO LI J 2007-08-30 US claimed
US-20100099719-A1 COMPOSITION AND METHOD FOR TREATING PROTEINURIA DIEREPHARMA, INC. (US) 2010-04-22 US disclosed
US-20090258911-A1 COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES TAO LI JIAN 2009-10-15 US disclosed
US-20090005424-A9 Composition and Method for Treating Fibrotic Diseases TAO LI J 2009-01-01 US disclosed
US-20080319027-A1 Composition and Method for Treating Fibrotic Diseases TAO LI JIAN 2008-12-25 US disclosed
EP-1878428-A1 1-(SUBSTITUTED PHENYL)-5- METHYL- 2 - (1H) PYRIDONE IN THE MANUFACTURE OF MEDICAMENTS FOR TREATING FIBROSIS IN ORGANS OR TISSUES Xiangya Hospital of Central South University (CN) 2008-01-16 EP disclosed
US-20070203203-A1 Composition and Method for Treating Fibrotic Diseases TAO LI J 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099719-A1 COMPOSITION AND METHOD FOR TREATING PROTEINURIA REN, PTPRF, PPM1F ALDH1A1 341/4885HSD17B10 632/4885KDM4E 280/4885
US-20090005424-A9 Composition and Method for Treating Fibrotic Diseases COL1A1, COL2A1, MMP1 ALDH1A1 485/4885HSD17B10 685/4885KDM4E 317/4885
US-20080319027-A1 Composition and Method for Treating Fibrotic Diseases COL1A1, COL2A1, MMP1 ALDH1A1 485/4885HSD17B10 685/4885KDM4E 317/4885
US-20090258911-A1 COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES COL1A1, COL2A1, MMP1 ALDH1A1 485/4885HSD17B10 685/4885KDM4E 317/4885
US-20070203203-A1 Composition and Method for Treating Fibrotic Diseases COL1A1, COL2A1, MMP1 ALDH1A1 485/4885HSD17B10 685/4885KDM4E 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.